# Great Novel Therapeutics Biotech & Medicals Corporation: Phase 1 study in Solid Tumor (Phase I), Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) (70 participants)

**Score:** 50/100

| Field | Value |
|---|---|
| Sponsor | Great Novel Therapeutics Biotech & Medicals Corporation |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Phase 1a/1b Clinical Trials to Evaluate the Safety and Preliminary Efficacy of GNTbm-38. |
| NCT ID | NCT07842445 |
| Phase | Phase 1 |
| Status | not yet recruiting |
| Conditions | Solid Tumor (Phase I); Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) |
| Intervention types | drug |
| Target enrollment | 70 |
| Posted | 2026-09-25 |
| Planned start | 2026-12-01 |
| Event | Newly registered study |
| Event date | 2026-09-25 |

## Why this score
- Industry sponsor (buys outsourced services).
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07842445). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.